Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Derisomaltose Injection Bioequivalence Study in Iron Deficiency Anemia
NCT07790562Phase 1Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration of total iron in serum, Area under the plasma concentration-time curve from time 0 to the last measurable concentration of total iron in serum and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT07790562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790562.